Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.

International journal of oncology - 1 Nov 2009

Liang Yayun, Besch-Williford Cynthia, Hyder Salman M

Abstract excerpt

Mutation of the p53 tumor suppressor gene is a common event in many types of tumors, including breast cancers. Mutant p53 (mtp53) protein is thought to promote tumor cell survival and resistance to chemotherapeutic drugs. Therefore, restoring p53 function by converting existing mtp53 to the wild-type p53 (wtp53) conformation is being pursued as one strategy to promote apoptosis of tumor cells. PRIMA-1 (p53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis
Share to Aza Compounds

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Blotting, Western

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Fluorescent Antibody Technique

Share to Mice, Nude

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 19787255
DOI: 10.3892/ijo_00000416

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.PMID 19787255Read ↗

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.Semantic proximity Read ↗

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.Semantic proximity Read ↗

PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.Semantic proximity Read ↗

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?Semantic proximity Read ↗

Restoration of p53 to limit tumor growth.Semantic proximity Read ↗

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.Semantic proximity Read ↗

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesSemantic proximity Read ↗

Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis.Semantic proximity Read ↗

PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.Semantic proximity Read ↗

PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.Semantic proximity Read ↗

p53 as a target for the treatment of cancer.Semantic proximity Read ↗

Novel cancer therapy by reactivation of the p53 apoptosis pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.